May 30, 2016
Recommended Topic Related To:


"The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for lesinurad (Zurampic, AstraZeneca AB) for the treatment of hyperuricemia in combination with a xanthine o"...





No reports of overdosage with KRYSTEXXA have been reported. The maximum dose that has been administered as a single intravenous dose is 12 mg as uricase protein.

Patients suspected of receiving an overdose should be monitored, and general supportive measures should be initiated as no specific antidote has been identified.


Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency

KRYSTEXXA is contraindicated in patients with G6PD deficiency due to the risk of hemolysis and methemoglobinemia. It is recommended that patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) be screened for G6PD deficiency before starting KRYSTEXXA.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 5/23/2016


Krystexxa - User Reviews

Krystexxa User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Krystexxa sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.